Mangoceuticals (MGRX) Registration Filing summary

Company overview and business model

• Operates a telehealth platform connecting consumers to licensed healthcare professionals for men's wellness products and services, including ED, hair loss, testosterone therapies, and weight management.

• Commercializes brands such as Mango (ED), Grow (hair loss), Mojo (hormone therapy), and Slim (weight loss), and markets an FDA-approved oral testosterone replacement therapy.

Financial performance and metrics

• As of June 13, 2025, public float was $24,897,620 based on 956,668 shares held by non-affiliates at $2.57 per share.

• 10,644,458 shares of common stock outstanding as of the filing date.

• Aggregate market value of common equity held by non-affiliates is below $75 million, limiting public primary offerings to one-third of public float in any 12-month period.

Use of proceeds and capital allocation

• Net proceeds intended for working capital and general corporate purposes.

• May use a portion for acquisitions or investments in complementary businesses or assets, though no current commitments exist.

• Pending use, proceeds will be invested in short-term, interest-bearing, investment-grade securities.